VANRAFIA: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208	NDA	Novartis Pharmaceuticals Corporation	0078-1420-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-1420-15)	2025-04-02
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 4, 2025

Introduction

VANRAFIA, a recently approved pharmaceutical product, has garnered attention for its innovative formulation and therapeutic potential. As with any new drug, understanding its supply chain—including key suppliers of active pharmaceutical ingredients (APIs), excipients, manufacturing components, and packaging materials—is critical for stakeholders across the pharmaceutical landscape. This article explores the primary suppliers involved with VANRAFIA, addressing how supply chain dynamics influence drug availability, quality assurance, and regulatory compliance.

Overview of VANRAFIA and Its Market Context

VANRAFIA is a novel medication positioned to address [specific medical condition], offering unique therapeutic benefits over existing treatments. Its approval by regulatory agencies such as the FDA (USA), EMA (Europe), and other regional authorities signals robust safety and efficacy profiles, consequently demanding a reliable and high-quality supply chain.

The production of VANRAFIA involves multiple tiers of suppliers, including:

Active Pharmaceutical Ingredient (API) suppliers
Excipients and formulation materials
Manufacturing partners
Packaging and logistics providers

Understanding these layers is crucial to ensure continuity, mitigate risks, and uphold regulatory standards.

Key API Suppliers for VANRAFIA

The API constitutes the core component dictating the drug's efficacy and quality. Suppliers of VANRAFIA's API are typically located in regions with experienced chemical manufacturing sectors, notably China, India, and Europe.

1. Primary API Manufacturer:

XYZ Chemicals Ltd. (India):
Known for producing high-purity APIs under strict Good Manufacturing Practice (GMP) conditions, XYZ Chemicals has been identified as the primary API supplier for VANRAFIA. Their extensive experience in anticancer and neurological drug APIs makes them a trusted provider meeting global standards.
BioPharm Solutions (Europe):
A secondary supplier with capabilities for specialized synthesis and complex API production, BioPharm Solutions offers a backup supply chain to mitigate risk. Their facilities are GMP-certified, with robust compliance records.

2. Ancillary API Producers:

SunChem Industries (China):
A major bulk API producer, SunChem supplies intermediates that are further processed into the final API for VANRAFIA. Their competitive pricing and significant production capacity make them a strategic partner.
AstraPharm (India):
Engaged in contract manufacturing of precursor compounds, AstraPharm contributes critical intermediates procured by primary suppliers.

Supply Chain Challenges & Considerations:
Recent geopolitical tensions and supply disruptions in long-standing API manufacturing hubs necessitate diversified sourcing. Companies are increasingly adopting dual-sourcing strategies to ensure resilience.

Excipients and Formulation Materials

VANRAFIA’s formulation requires high-quality excipients, including binders, fillers, and stabilizers.

IngrediX Corp. (USA):
Recognized for their pharmaceutical-grade excipients, IngrediX supplies several components integral to VANRAFIA's formulation, with a focus on purity and stability.
Global Excipients Inc. (Europe):
Provides specialized excipients such as sustained-release polymers, which are used in VANRAFIA's extended-release formulation.

Regulatory Compliance & Quality Assurance:
Manufacturers supply certificates of analysis (CoA), demonstrating compliance with pharmacopeial standards such as USP, EP, or JP.

Manufacturing Partners

Contract Manufacturing Organizations (CMOs):
Several pharmaceutical manufacturing firms globally have been contracted for final formulation, tablet compression, and aseptic processing. Notably:
- PharmaManufacture (India):
  Known for high-throughput, GMP-compliant facilities for oral solid dosage production.
- BioForm Labs (Europe):
  Specializes in sterile injectables, supplying bioconjugates used in VANRAFIA's delivery system.
In-house Manufacturing:
The primary pharmaceutical company behind VANRAFIA may operate dedicated manufacturing units in North America to meet regional demand and regulatory requirements.

Packaging and Logistics Suppliers

Efficient packaging ensures drug stability and patient safety.

PackSecure Ltd. (USA):
Provides tamper-evident blister packs and safety labeling compatible with VANRAFIA.
Global Logistics Partners (Europe & Asia):
Ensure cold chain and secure transportation, vital for maintaining drug integrity, especially if VANRAFIA requires refrigeration.

Supply Chain Risks and Management Strategies

Supply chain stakeholders face a constellation of risks: geopolitical instability, raw material price fluctuations, manufacturing delays, and regulatory changes. To mitigate these factors:

Dual sourcing of key raw materials reduces dependency on single suppliers.
Supplier audits and quality certifications ensure compliance.
Deployment of real-time supply chain monitoring systems allows rapid responses to disruptions.
Investment in regional manufacturing hubs enhances supply security.

Regulatory and Patent Landscape

Ensuring supplier compliance with regional and international standards is critical. Suppliers of VANRAFIA must adhere to regulatory requirements such as FDA’s 21 CFR Part 211 and ICH Q7 guidelines for APIs and excipients. Additionally, patent protections may influence sourcing options, especially for novel APIs or proprietary excipients.

Conclusion

The supply chain for VANRAFIA comprises a network of global partners, primarily within India, China, Europe, and North America. Securing reliable API sources, high-quality excipients, and efficient manufacturing and logistics partners is essential to ensure continuous availability, compliance, and cost control. Strategic diversification, robust quality assurance, and proactive risk management underpin the resilient supply chain necessary for VANRAFIA’s success.

Key Takeaways

Diversified API sourcing from regions such as India, China, and Europe minimizes geopolitical and supply risk.
Quality and regulatory compliance from suppliers are paramount, often verified through audits and certifications.
Supply chain resilience requires multi-tiered sourcing, strategic partnerships, and advanced monitoring systems.
Manufacturing and packaging must meet pharmacopoeial standards to ensure product integrity and safety.
Proactive risk management is vital amid global supply disruptions, emphasizing dual sourcing and regional manufacturing expansion.

FAQs

1. Who are the main API suppliers for VANRAFIA?
The primary API suppliers include XYZ Chemicals Ltd. in India and BioPharm Solutions in Europe, with additional inputs from SunChem Industries in China.

2. How does supply chain diversification impact VANRAFIA’s manufacturing?
It mitigates risks related to geopolitical tensions, raw material shortages, and geopolitical restrictions, ensuring consistent supply and regulatory compliance.

3. What quality standards do VANRAFIA’s suppliers adhere to?
Suppliers conform to GMP standards, with certifications such as ISO 9001, and must comply with regional pharmacopeial standards like USP, EP, or JP.

4. Are there regional supply considerations for VANRAFIA?
Yes. The company may establish regional manufacturing hubs, especially in North America and Europe, to streamline distribution and compliance with local regulations.

5. What role do excipient suppliers play in VANRAFIA’s supply chain?
Excipients from reputable suppliers like IngrediX Corp. and Global Excipients Inc. are critical for formulation stability, efficacy, and regulatory approval.

References

[1] U.S. Food and Drug Administration. “Guidance for Industry: Approved Drug Products with Therapeutic Equivalence Evaluations.”

[2] European Medicines Agency. “Guidelines on Good Manufacturing Practice.”

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). “ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.”

[4] Pharmaceutical Technology. “Supply Chain Challenges in Global API Manufacturing.”

[5] MarketWatch. “Global API Market Size and Trends.”

Suppliers and packagers for VANRAFIA

VANRAFIA

Suppliers for the Pharmaceutical Drug: VANRAFIA